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dose-speciﬁc efﬁcacy of SPAA at reducing systolic blood pressure
and total cholesterol were drawn from published clinical trial
data (RESPOND), while costs were sourced from Korean phar-
maceutical pricing lists. SPAA comprised weighted average doses
of the ﬁxed-dose combinations of amlodipine 5 mg / atorvastatin
10 mg and 5 mg/20 mg, based on market distribution in Korea.
A 20% price reduction after one year was implemented to reﬂect
patent expiry. Costs of CVD were derived from 2008 Korean
Health Insurance Review and Assessment Service (HIRA) esti-
mates. Utility values for CVD were obtained from published
literature based on 2005 KNHANES data. RESULTS: Compared
to placebo (no treatment), the incremental cost-effectiveness
ratios associated with SPAA were 1,428,681 Korean won (KW)/
QALY and 1,989,858 KW/YoLS. (One thousand KW equates to
approximately one US dollar.) Sensitivity analyses indicated these
results to be robust. CONCLUSIONS: SPAA represents a cost-
effective strategy for the primary prevention of CVD in Korea.
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OBJECTIVES: Chronic heart failure (CHF) is associated with a
substantial clinical and economic burden that impacts signiﬁ-
cantly on health care systems. The objective of this study is to
assess the cost-utility of a new home telemonitoring (HTM)
project in elderly CHF outpatients. METHODS: This prospec-
tive, 6-month, randomised trial was designed to compare the
cost-effectiveness of a HTM project versus usual care (UC) in
elderly patients with CHF, receiving optimal treatment and coun-
selling. A total of 24 patients (aged 66–92 years) were assigned
randomly to HTM or UC. At baseline and at the end of the study,
all patients had a complete cardiologist’s assessment, including
quality of life. The evaluation of the cost of HTM includes the
cost of drug therapy, monitoring, treating side-effects, hospital-
izations and devices. All costs were calculated from a third-party
payer perspective, in 2007 Euros. RESULTS: The mean duration
of the follow-up was similar for the two groups (136.92  36.65
days, P > 0.05). There was a non-statistically signiﬁcant reduc-
tion in hospital readmissions, hospitalisation days, physicians’
visits, laboratory tests and total costs (P > 0.05) for HTM group.
However, HTM was associated with a signiﬁcant improvement
in the QoL measured with the generic health-related EQ-5D
questionnaire (10.00  7.24, P < 0.001) and a small incremental
gain of 0.13  0.24 quality-adjusted-life-years (QALYs) over
UC. The analysis showed that the average incremental cost of
HTM was €12,909  €53,313/QALY gained. CONCLUSIONS:
HTM is likely to be a cost-effective intervention compared with
UC in elderly CHF outpatients in Greece. However, further
studies with more patients and longer duration are needed to
conﬁrm these results.
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OBJECTIVES: To investigate the potential beneﬁt of adding
genetic testing to a pharmacist-managed anticoagulation service
for hospitalized patients on warfarin. METHODS: Using deci-
sion analytic modeling we constructed a decision tree model. The
decisions used were a treat-all and a treat-none approach. The
outcome of interest was minimizing the number of adverse events
(bleeding or thrombitic event). Model parameters were primarily
based on institutional data. Additional information from the
literature or expert opinion was used if needed. One-way sensi-
tivity analyses were performed on unknown parameters to deter-
mine decision thresholds. Two parameters, percentage of patients
beneﬁting from testing and rate of reduction of adverse event
rates due to genetic test results, were given special attention as no
prior information is available. Probabilistic sensitivity analysis
was also conducted. A willingness-to-pay of $35,000 per avoided
adverse event was used as the decision threshold. RESULTS:
Sensitivity analysis showed the decision choice to be affected by
the values of both parameters of interest (20% prevalence and
8% reduction respectively). Baseline analysis resulted in the
treat-all approach to cost an additional $102 per patient on
average and avoid 8 adverse events per 10,000 patients. Proba-
bilistic analysis determined the point at which each decision was
equally likely to be optimal was at a willingness-to-pay of
$140,000. Holding the reduction rate constant the rate of
patients beneﬁtting from the test would need to be as high as
40% before the treat-all approach becomes optimal. Similarly,
the reduction rate would need to be as high as 16% for the
treat-all approach to be optimal. CONCLUSIONS: The percent-
age of patients that would beneﬁt from testing, as well as the
reduction in adverse event rates due to testing, inﬂuence the
decision of treatment approach. The addition of testing all
patients could potentially be cost-effective with sufﬁciently high
enough prevalence and adverse event reduction rates.
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OBJECTIVES: Contrast-induced adverse drug reactions (ADRs),
including contrast-induced nephropathy, are common among
high-risk patients undergoing angiography (e.g., patients with
diabetes mellitus and renal impairment). These ADRs cause
extended hospital stays and additional medication use, leading to
increased cost. We examine the cost-effectiveness of the use of 2
contrast media, in patients at high risk of contrast-induced ADRs,
from the perspective of 5 European countries (Germany, Italy,
Spain, Sweden, and UK). METHODS: A multi-country decision-
analytic model was constructed to estimate the cost-effectiveness
of an isosmolar contrast agent (iodixanol) compared to a low-
osmolar contrast medium (iohexol). The emphasis of the model
was to consider differences in the incidence of severe ADRs in
patients at high risk of contrast-induced nephropathy. The analy-
sis was based on a European randomised controlled trial
(NEPHRIC), in which patients receiving angiography with iodix-
anol had statistically fewer severe ADRs than those with iohexol.
Patients in the study were 18 years of age or older, referred for
coronary or aortofemoral angiography, and had diabetes with
stable serum creatinine concentrations (men: 1.5 to 3.5 mg/dL;
women: 1.3 to 3.5 mg/dL). ADRs considered included acute renal
failure, arrhythmia, cardiovascular events, pulmonary edema, and
multiple-organ failure. Resource use, including hospital days,
medical visits, contrastmedium,medications, laboratory tests and
hospital procedures, were obtained from the NEPHRIC clinical
Abstracts A397
